Expanding Applications and Updates in CNS Tumor Classification Guidelines – from research and boutique to broad clinical application

Hosted on Acast. See acast.com/privacy for more information.

This podcast features George Busby discussing his work on polygenic risk scores (PRS) and their expanding role in precision medicine. He reflects on how he became interested in PRS, recent advances in methylation risk scores (MRS), and the potential of integrating PRS and MRS to improve disease prediction. The conversation highlights his breast cancer study in Colombian women, exploring its hypothesis, findings, and global relevance. Busby also addresses challenges in translating genomic research into clinical practice, efforts to enhance predictive models, and how technological evolution continues to drive innovation and future directions in genomic medicine. Hosted on Acast. See acast.com/privacy for more information.

This Inside Precision Medicine podcast explores how advances in DNA methylation research are transforming diabetes care. The discussion with Charlotte Ling covers motivations for focusing on methylation as valuable prognosticator of disease, the advantages of methylation risk scores (MRS) compared to polygenic risk scores (PRS), and novel gene associations linked to cardiovascular complications in diabetes. She articulates the validation needs across diverse populations, the influence of lifestyle on methylation stability, and strategies for translating these biomarkers into clinical tools. Finally, she reflects on evolving technologies, future applications of methylation biomarkers, and the potential for precision diagnostics and targeted interventions in high-risk diabetic patients. Hosted on Acast. See acast.com/privacy for more information.

Providing a roadmap for laboratories to adopt DNA methylation-based tumor classification, addressing workflow design, operational challenges, and community engagement. Discuss financial barriers and obstacles Hosted on Acast. See acast.com/privacy for more information.

Exploring the growing role of DNA methylation in classifying and predicting prognosis for sarcomas, while highlighting integration with array, NGS, and CNV analysis for complex profiling. And other tumors and applications Hosted on Acast. See acast.com/privacy for more information.

How DNA methylation changed clinical management of CNS tumors and is being integrated into clinical guidelines, including cIMPACT-NOW updates and the impact of technological advances. Hosted on Acast. See acast.com/privacy for more information.

This IPM podcast highlights the impressive work of Lucas Santana dos Santos, director of bioinformatics and an assistant professor at Northwestern University’s Feinberg School of Medicine. Professor dos Santos discusses the origins and recent developments of molecular tumor classification techniques and how analyzing epigenetic signatures is enabling clinicians to diagnose and treat cancer patients more effectively. This illuminating conversation examines how classifiers are developed and touches on the role of various technologies including the workhorse methylation microarray, in addition to the challenges of creating a universal tumor classifier. Hosted on Acast. See acast.com/privacy for more information.

This IPM podcast unpacks some of the important work being done by Emma Johnson PhD Assistant Professor | Department of Psychiatry Washington University School of Medicine - we discuss her mission to elucidate the genetic architecture of psychiatric disorders, particularly focusing on substance use and addictions. We hear about her ongoing research in understanding commonly used drugs such as alcohol and cannabis and the relationships between substance use disorders and other psychiatric disorders and mental health conditions, including schizophrenia, suicidal thoughts and behaviors, and chronic pain. Hosted on Acast. See acast.com/privacy for more information.

In this new Inside Precision Medicine Podcast episode, sponsored by Illumina, we speak with Dr. Julio Monterrey, a Stanford-trained, board-certified psychiatrist and neuroscientist who specializes in diagnosing and treating complex cases. Dr. Monterrey is a keen observer of medical technology who has adopted pharmacogenetic (PGx) testing as a regular part of patient history taking. Through his experience, Dr. Monterrey has seen substantial benefits from PGx testing for his patients and his practice. He is now an advocate for wider adoption of PGx screening to guide and improve patient care. We spoke with Dr. Monterrey to hear what he has learned working with PGx testing in his psychiatry practice. Hosted on Acast. See acast.com/privacy for more information.